Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 7481 results found since Jan 2013.
A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
J Drugs Dermatol. 2023 Aug 1;22(8):761-765. doi: 10.36849/jdd.7481.ABSTRACTPsoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psoriasis. With proven efficacy and safety, topical corticosteroids are often used, although adverse effects and limitations for use exist. Tapinarof (Vtama®), a novel topical aryl hydrocarbon receptor modulating drug, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults in May 2022. A literature search ...
Source: Journal of Drugs in Dermatology - August 9, 2023 Category: Dermatology Authors: Julie Kalabalik-Hoganson Anna Nogid Kathleen Frey Source Type: research
Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis
This study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate bleomycin-induced biochemical derangements and histological changes in an experimental PF rat model. This can provide the means to validate the clinical utility of ivermectin as a treatment option for idiopathic PF. The results showed that ivermectin mitigated the bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin decreased collagen fiber deposition and suppressed transforming growth factor-β1 (TGF-β1) and ...
Source: J Zhejiang Univ Sci ... - August 8, 2023 Category: Science Authors: Mai A Abd-Elmawla Heba R Ghaiad Enas S Gad Kawkab A Ahmed Maha Abdelmonem Source Type: research
